IHL : Pre-IND meeting granted with the US FDA regarding IHL-675A for use in preventing ARDS and SAARDS

The purpose of the meeting is to obtain regulatory guidance and agreement on the most efficient clinical development plan to be included in an investigational new drug (‘IND’) application for IHL-675A in the prevention of ARDS and SAARDS in the United States.